par
Gus Iversen, Editor in Chief | April 13, 2026
Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center have begun early construction activity on a planned 300-bed inpatient cancer hospital, starting with the deconstruction of the former Joslin Diabetes Center building at One Joslin Place.
The milestone follows a two-year transition in which the Boston-based Joslin Diabetes Center relocated its clinical and research operations to other facilities on Beth Israel Deaconess Medical Center’s East Campus and the Center for Life Science. Clearing the site allows work to proceed on the new hospital, first announced in 2023.
Plans call for a 450,000-square-foot facility with 10 inpatient floors focused exclusively on oncology care. The project is intended to expand inpatient capacity and support care delivery as cancer incidence rises. Construction is expected to continue through a targeted opening in 2031.
Ad Statistics
Times Displayed: 10932
Times Visited: 33 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
“Kicking off this construction process is a tremendous step forward in the Dana-Farber Beth Israel Deaconess Cancer Collaboration as we transform the future of cancer care in the region,” said Pete Healy, president, Beth Israel Deaconess Medical Center and divisional president, Metro Boston, Beth Israel Lahey Health. “Our teams will continue working closely together in the months ahead to ensure our surrounding community, patients, staff, and visitors to the Longwood Medical Area are kept updated on any impacts.”
The hospital will be located in Boston’s Longwood Medical Area and is designed to integrate with existing Dana-Farber and BIDMC facilities. The organizations said the campus layout will support coordination across inpatient and outpatient oncology services.
“This moment brings us closer to a new inpatient cancer hospital that will enable us to continue setting the standard for cancer care here in Boston and around the world,” said Dr. William C. Hahn, executive vice president and chief operating and transformation officer at Dana-Farber Cancer Institute.
Clinical operations at the new hospital will be supported through collaboration among Dana-Farber, BIDMC, and Harvard Medical Faculty Physicians.
